The publisher regrets that the two sections under the Results omitted inadvertently on the original published version of the above article. The text are as follows:
Pulmonary function test results
Among the subjects included in the study, 188 subjects had PFTs performed for clinical indications. Seropositive subjects had lower median % predicted FEV1 80%, IQR 59-93%) compared with seronegative subjects (89.5%, IQR 70-101%; p = 0.034). While there were no statistical differences between seropositive and seronegative RA for FVC, FEV1/FVC, or DLCO, the seropositive subjects tended to have lower results (Table 2 ). Any PFT abnormality was observed in 84 seropositive subjects and 16 seronegative subjects. Table 3 shows the unadjusted and multivariableadjusted as sociations of RA serostatus with the primary composite outcome of any PFT abnormality (restriction, obstruction, or diffusion abnormality) on clinically indicated PFTs. Seropositivity was significantly associated with increased odds of any PFT abnormality (OR 2.29, 95% CI 1.30-4.03), adjusted for age, sex, education, smoking status, BMI, and RA duration. Combined CCP and RF positivity had multivariable OR of 1.67 (95%CI 1.03-2.69) and 1.99 (95%CI 1.21-3.27), for any PFT abnormality compared with CCP and RF negativity, respectively. There was no statistically significant dose effect of CCP titer for the primary outcome (p for trend 0.061). However, the RF titer dose effect had a statistically significant p for trend at 0.001, such that high-titer RF was associated with two-fold increased odds for any PFT abnormality (OR 2.29, 95%CI 1.37-3.84) compared with RF−. In subjects with discordant CCP/RF patterns, CCP−/RF+ tended to have a stronger association with any PFT abnormality (OR 2.78, 95% CI 1.20-6.44) than CCP+/RF− (OR 1.91, 95% CI 0.75-4.87), when compared with CCP−/RF−. 
RA-related autoantibodies and any pulmonary function test abnormality

